Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edwards Lifesciences CorpEW · Entity 3026 | CVP, TAVR | October 08, 2026 | October 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edwards Lifesciences Corp
Report date October 08, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,033.9103 |
Ending reported balance
After 2026-10-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-08 · Exercise / conversion · Acquired 619 · Balance 40,652.9103 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. Row 2 · 2026-10-08 · Sale · Disposed 619 · Balance 40,033.9103 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. |
| Employee Stock Option (Right to Acquire)SEC Table II · derivative / convertible security · Conversion / exercise price $72.68 · Expires 2027-05-06 | Direct | 3,095 |
Reported balance
After 2026-10-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-08 · Exercise / conversion · Disposed 619 · Balance 3,095 |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 08, 2026 Filed Oct 8, 2026 21:24 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 619 | $0.00 Strike: $72.68 | $0.00 |
DisclosureSEC source: 0001225208-26-008338 · doc4.xml · derivative · entry 3 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,095 Underlying: Common Stock · 619 shares Expires 2027-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 08, 2026 Filed Oct 8, 2026 21:24 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 619 | $85.65 | $53,017.35 |
DisclosureSEC source: 0001225208-26-008338 · doc4.xml · nonDerivative · entry 2 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,033.9103 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. Read SEC document |
| October 08, 2026 Filed Oct 8, 2026 21:24 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 619 | $72.68 | $44,988.92 |
DisclosureSEC source: 0001225208-26-008338 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,652.9103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 23:15 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 619 | $0.00 Strike: $72.68 | $0.00 |
DisclosureSEC source: 0001225208-26-007774 · doc4.xml · derivative · entry 3 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,714 Underlying: Common Stock · 619 shares Expires 2027-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 23:15 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 619 | $87.51 | $54,168.69 |
DisclosureSEC source: 0001225208-26-007774 · doc4.xml · nonDerivative · entry 2 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,033.9103 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 23:15 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 619 | $72.68 | $44,988.92 |
DisclosureSEC source: 0001225208-26-007774 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,652.9103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. Read SEC document |
| August 11, 2026 Filed Aug 11, 2026 21:07 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 619 | $0.00 Strike: $72.68 | $0.00 |
DisclosureSEC source: 0001225208-26-007065 · doc4.xml · derivative · entry 3 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,333 Underlying: Common Stock · 619 shares Expires 2027-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2026 Filed Aug 11, 2026 21:07 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 619 | $92.03 | $56,966.57 |
DisclosureSEC source: 0001225208-26-007065 · doc4.xml · nonDerivative · entry 2 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,033.9103 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. Read SEC document |
| August 11, 2026 Filed Aug 11, 2026 21:07 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 619 | $72.68 | $44,988.92 |
DisclosureSEC source: 0001225208-26-007065 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,652.9103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. Read SEC document |
| July 10, 2026 Filed Jul 10, 2026 21:04 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 619 | $0.00 Strike: $72.68 | $0.00 |
DisclosureSEC source: 0001225208-26-006576 · doc4.xml · derivative · entry 3 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,952 Underlying: Common Stock · 619 shares Expires 2027-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 10, 2026 Filed Jul 10, 2026 21:04 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 619 | $91.70 | $56,762.30 |
DisclosureSEC source: 0001225208-26-006576 · doc4.xml · nonDerivative · entry 2 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,033.9103 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. Read SEC document |
| July 10, 2026 Filed Jul 10, 2026 21:04 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 619 | $72.68 | $44,988.92 |
DisclosureSEC source: 0001225208-26-006576 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,652.9103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. Read SEC document |
| July 07, 2026 Filed Jul 7, 2026 22:56 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 377 | $95.18 | $35,882.86 |
DisclosureSEC source: 0001225208-26-006535 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,033.9103 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations incident to the vesting of securities in accordance with Rule 16b-3(e). Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 00:01 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 619 | $0.00 Strike: $72.68 | $0.00 |
DisclosureSEC source: 0001225208-26-006263 · doc4.xml · derivative · entry 3 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,571 Underlying: Common Stock · 619 shares Expires 2027-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 00:01 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 619 | $91.40 | $56,576.72 |
DisclosureSEC source: 0001225208-26-006263 · doc4.xml · nonDerivative · entry 2 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,410.9103 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. F2 · price: This transaction was executed in multiple trades at prices ranging from $91.185 to $91.650. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 00:01 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 619 | $72.68 | $44,988.92 |
DisclosureSEC source: 0001225208-26-006263 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,029.9103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. Read SEC document |
| May 18, 2026 Filed May 18, 2026 21:29 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 620 | $0.00 Strike: $72.68 | $0.00 |
DisclosureSEC source: 0001225208-26-005464 · doc4.xml · derivative · entry 3 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,190 Underlying: Common Stock · 620 shares Expires 2027-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2026 Filed May 18, 2026 21:29 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 620 | $81.14 | $50,306.80 |
DisclosureSEC source: 0001225208-26-005464 · doc4.xml · nonDerivative · entry 2 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,410.9103 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. Read SEC document |
| May 18, 2026 Filed May 18, 2026 21:29 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 620 | $72.68 | $45,061.60 |
DisclosureSEC source: 0001225208-26-005464 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,030.9103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. Read SEC document |
| May 11, 2026 Filed May 12, 2026 01:32 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 362 | $79.96 | $28,945.52 |
DisclosureSEC source: 0001225208-26-005130 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,410.9103 Read SEC document |
| May 08, 2026 Filed May 9, 2026 01:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 450 | $82.76 | $37,242.00 |
DisclosureSEC source: 0001225208-26-005045 · doc4.xml · nonDerivative · entry 3 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,772.9103 Read SEC document |
| May 07, 2026 Filed May 9, 2026 01:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantPerformance Rights · Derivative | 7,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005045 · doc4.xml · derivative · entry 5 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,850 Underlying: Common Stock · 7,850 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2029. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 200% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2029. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 200% of the Target Awards. Read SEC document |
| May 07, 2026 Filed May 9, 2026 01:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 39,900 | $0.00 Strike: $82.76 | $0.00 |
DisclosureSEC source: 0001225208-26-005045 · doc4.xml · derivative · entry 4 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,900 Underlying: Common Stock · 39,900 shares Expires 2033-05-06 F2 · derivative.exercise_date: These options were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 07, 2026 Filed May 9, 2026 01:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 309 | $83.20 | $25,708.80 |
DisclosureSEC source: 0001225208-26-005045 · doc4.xml · nonDerivative · entry 2 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,222.9103 Read SEC document |
| May 07, 2026 Filed May 9, 2026 01:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 7,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005045 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,531.9103 F1 · shares: These restricted stock units were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 04, 2026 Filed May 4, 2026 23:30 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 1,019 | $0.00 Strike: $59.26 | $0.00 |
DisclosureSEC source: 0001225208-26-004909 · doc4.xml · derivative · entry 8 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,019 shares Expires 2026-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2026 Filed May 4, 2026 23:30 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,019 | $83.98 | $85,575.62 |
DisclosureSEC source: 0001225208-26-004909 · doc4.xml · nonDerivative · entry 6 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,681.9103 Read SEC document |
| May 04, 2026 Filed May 4, 2026 23:30 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 1,019 | $59.26 | $60,382.58 |
DisclosureSEC source: 0001225208-26-004909 · doc4.xml · nonDerivative · entry 5 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,700.9103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2026 Filed May 4, 2026 23:30 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 252 | $83.98 | $21,162.96 |
DisclosureSEC source: 0001225208-26-004909 · doc4.xml · nonDerivative · entry 4 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,681.9103 Read SEC document |
| May 01, 2026 Filed May 4, 2026 23:30 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 1,019 | $0.00 Strike: $59.26 | $0.00 |
DisclosureSEC source: 0001225208-26-004909 · doc4.xml · derivative · entry 7 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,019 Underlying: Common Stock · 1,019 shares Expires 2026-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2026 Filed May 4, 2026 23:30 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,000 | $82.99 | $82,988.90 |
DisclosureSEC source: 0001225208-26-004909 · doc4.xml · nonDerivative · entry 3 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,933.9103 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $82.540 to $83.490. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 01, 2026 Filed May 4, 2026 23:30 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 19 | $83.99 | $1,595.77 |
DisclosureSEC source: 0001225208-26-004909 · doc4.xml · nonDerivative · entry 2 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,933.9103 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $83.980 to $84.095. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 01, 2026 Filed May 4, 2026 23:30 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 1,019 | $59.26 | $60,382.58 |
DisclosureSEC source: 0001225208-26-004909 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,952.9103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025. Read SEC document |
| April 06, 2026 Filed Apr 7, 2026 00:42 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 1,019 | $0.00 Strike: $59.26 | $0.00 |
DisclosureSEC source: 0001225208-26-004422 · doc4.xml · derivative · entry 3 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,038 Underlying: Common Stock · 1,019 shares Expires 2026-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 06, 2026 Filed Apr 7, 2026 00:42 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,019 | $80.98 | $82,522.70 |
DisclosureSEC source: 0001225208-26-004422 · doc4.xml · nonDerivative · entry 2 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,933.9103 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $80.64 to $81.07. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 06, 2026 Filed Apr 7, 2026 00:42 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 1,019 | $59.26 | $60,382.58 |
DisclosureSEC source: 0001225208-26-004422 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,952.9103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025. Read SEC document |
| March 11, 2026 Filed Mar 11, 2026 21:10 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 1,019 | $0.00 Strike: $59.26 | $0.00 |
DisclosureSEC source: 0001225208-26-003538 · doc4.xml · derivative · entry 3 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,057 Underlying: Common Stock · 1,019 shares Expires 2026-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 11, 2026 Filed Mar 11, 2026 21:10 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,019 | $85.38 | $87,004.46 |
DisclosureSEC source: 0001225208-26-003538 · doc4.xml · nonDerivative · entry 2 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,933.9103 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $85.16 to $85.76. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide,uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 11, 2026 Filed Mar 11, 2026 21:10 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 1,019 | $59.26 | $60,382.58 |
DisclosureSEC source: 0001225208-26-003538 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,952.9103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025. Read SEC document |
| February 22, 2026 Filed Feb 23, 2026 22:08 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 432 | $79.78 | $34,464.96 |
DisclosureSEC source: 0001225208-26-002409 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,933.9103 Read SEC document |
| February 17, 2026 Filed Feb 17, 2026 22:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 198 | $75.87 | $15,022.26 |
DisclosureSEC source: 0001225208-26-001986 · doc4.xml · nonDerivative · entry 3 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,365.9103 Read SEC document |
| February 16, 2026 Filed Feb 17, 2026 22:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 258 | $75.87 | $19,574.46 |
DisclosureSEC source: 0001225208-26-001986 · doc4.xml · nonDerivative · entry 2 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,563.9103 Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 22:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 12,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-001986 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,821.9103 F1 · shares: These restricted stock units were granted on February 12, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| January 09, 2026 Filed Jan 9, 2026 22:41 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 1,019 | $0.00 Strike: $59.26 | $0.00 |
DisclosureSEC source: 0001225208-26-000558 · doc4.xml · derivative · entry 3 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,076 Underlying: Common Stock · 1,019 shares Expires 2026-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 09, 2026 Filed Jan 9, 2026 22:41 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,019 | $85.70 | $87,332.07 |
DisclosureSEC source: 0001225208-26-000558 · doc4.xml · nonDerivative · entry 2 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,001.9103 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $85.45 to $85.95. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of theIssuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 09, 2026 Filed Jan 9, 2026 22:41 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 1,019 | $59.26 | $60,382.58 |
DisclosureSEC source: 0001225208-26-000558 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,020.9103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025. Read SEC document |
| December 12, 2025 Filed Dec 12, 2025 22:57 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 1,019 | $0.00 Strike: $59.26 | $0.00 |
DisclosureSEC source: 0001225208-25-009934 · doc4.xml · derivative · entry 3 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,095 Underlying: Common Stock · 1,019 shares Expires 2026-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2025 Filed Dec 12, 2025 22:57 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,019 | $84.03 | $85,625.25 |
DisclosureSEC source: 0001225208-25-009934 · doc4.xml · nonDerivative · entry 2 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,001.9103 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $83.58 to $84.46. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 12, 2025 Filed Dec 12, 2025 22:57 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 1,019 | $59.26 | $60,382.58 |
DisclosureSEC source: 0001225208-25-009934 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,020.9103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025. Read SEC document |
| November 10, 2025 Filed Nov 10, 2025 23:06 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 1,020 | $0.00 Strike: $59.26 | $0.00 |
DisclosureSEC source: 0001225208-25-009066 · doc4.xml · derivative · entry 3 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,114 Underlying: Common Stock · 1,020 shares Expires 2026-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.